{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:51:33Z","timestamp":1790380293996,"version":"4.1.0"},"reference-count":26,"publisher":"Endocrinology Research Centre","issue":"2","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Hepatogenic diabetes (HepD) is a form of diabetes where the primary pathogenesis is a liver disease, usually cirrhosis, complicated by the development of portal hypertension with the formation of porto-caval shunts. In the development of HepD, in addition to traditional risk factors for carbohydrate metabolism disorders, the pathogenetic features of liver diseases play a significant role. However, the exact mechanism of HepD development remains unclear, and several questions are still open for discussion. Despite having distinct pathophysiological and clinical features, hepatogenic diabetes is currently not considered as an independent disease. This is likely due to the difficulties in differentiating between types of diabetes due to the bidirectional relationship between glucose metabolism disorders and chronic liver diseases. It is known that diabetes negatively affects the development and progression of chronic liver diseases of various etiologies, and their combination is associated with worse clinical outcomes in terms of mortality, the occurrence of liver decompensation, and the development of hepatocellular carcinoma (HCC). Unfortunately, early diagnosis and the selection of optimal therapeutic strategies for diabetes may be challenging due to the lack of established clinical guidelines and the presence of comorbidities in patients with HepD.<\/jats:p>","DOI":"10.14341\/probl13443","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T15:37:53Z","timestamp":1747841873000},"page":"66-74","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":2,"title":["Hepatogenic diabetes: three cases report and literature review"],"prefix":"10.14341","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1848-8721","authenticated-orcid":true,"given":"M. V.","family":"Amosova","sequence":"first","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University (Sechenov University)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-3061","authenticated-orcid":true,"given":"I. V.","family":"Poluboyarinova","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University (Sechenov University)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2011-1237","authenticated-orcid":true,"given":"P. V.","family":"Salnikova","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University (Sechenov University)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0292-5907","authenticated-orcid":true,"given":"K. Y.","family":"Zherebchikova","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University (Sechenov University)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3026-6315","authenticated-orcid":true,"given":"V. V.","family":"Fadeev","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University (Sechenov University)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5458","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kalmykova ZA, Kononenko I V., Mayorov AY. Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features. Ter Arkh. 2019;91(12):115-121. doi: https:\/\/doi.org\/10.26442\/00403660.2019.12.000166","DOI":"10.26442\/00403660.2019.12.000166"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Compe\u00e1n D, Gonz\u00e1lez-Gonz\u00e1lez JA, Lavalle-Gonz\u00e1lez FJ, Gonz\u00e1lez-Moreno EI, Villarreal-P\u00e9rez JZ, Maldonado-Garza HJ. Hepatogenous diabetes: Is it a neglected condition in chronic liver disease? World J Gastroenterol. 2016;22(10):2869. doi: https:\/\/doi.org\/10.3748\/wjg.v22.i10.2869","DOI":"10.3748\/wjg.v22.i10.2869"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease. Diabetes Care. 2007;30(3):734-743. doi: https:\/\/doi.org\/10.2337\/dc06-1539","DOI":"10.2337\/dc06-1539"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Khan R, Foster GR, Chowdhury TA. Managing Diabetes in Patients with Chronic Liver Disease. Postgrad Med. 2012;124(4):130-137. doi: https:\/\/doi.org\/10.3810\/pgm.2012.07.2574","DOI":"10.3810\/pgm.2012.07.2574"},{"key":"ref5","unstructured":"Babenko AYu, Laevskaya MYu. Nealkogol\u2019naya zhirovaya bolezn\u2019 pecheni \u2014 vzaimosvyazi s metabolicheskim. Rmzh. 2018;1(1):34-40 (In Russ.) [Online]. Available: https:\/\/elibrary.ru\/item.asp?id=35663873"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Aky\u00fcrek N, Atabek ME, Eklioglu BS. Possible Associations of Acut Hepatitis B With New-onset Type 1 Diabetes: A Case Report. Gazi Med J. 2015;26(2). doi: https:\/\/doi.org\/10.12996\/gmj.2015.21","DOI":"10.12996\/gmj.2015.21"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chen LK, Chou YC, Tsai ST, Hwang SJ, Lee SD. Hepatitis C virus infection\u2010related Type 1 diabetes mellitus. Diabet Med. 2005;22(3):340-343. doi: https:\/\/doi.org\/10.1111\/j.1464-5491.2005.01412.x","DOI":"10.1111\/j.1464-5491.2005.01412.x"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Compe\u00e1n D, Orsi E, Kumar R, et al. Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives. World J Gastroenterol. 2022;28(8):775-793. doi: https:\/\/doi.org\/10.3748\/wjg.v28.i8.775","DOI":"10.3748\/wjg.v28.i8.775"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Elkrief L, Rautou P, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016;36(7):936-948. doi: https:\/\/doi.org\/10.1111\/liv.13115","DOI":"10.1111\/liv.13115"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kumar R. Hepatogenous diabetes: An underestimated problem of liver cirrhosis. Indian J Endocrinol Metab. 2018. doi: https:\/\/doi.org\/10.4103\/ijem.IJEM_79_18","DOI":"10.4103\/ijem.IJEM_79_18"},{"key":"ref11","unstructured":"Radchenko VG, Shabrov AV, Zinov\u2019eva EN. Osnovy klinicheskoj gepatologii. Sankt-Peterburg: s.404-407 BINOM, 2005. (In Russ.)"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Kumar R, Garc\u00eda-Compe\u00e1n D, Maji T. Hepatogenous diabetes: Knowledge, evidence, and skepticism. World J Hepatol. 2022;14(7):1291-1306. doi: https:\/\/doi.org\/10.4254\/wjh.v14.i7.1291","DOI":"10.4254\/wjh.v14.i7.1291"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"E. Orsi, V. Grancini, S. Menini, A. Aghemo, and G. Pugliese. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?. Liver Int. 2016;7(37);950-962. doi: https:\/\/doi.org\/10.1111\/liv.13337.","DOI":"10.1111\/liv.13337"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Coman LI, Coman OA, B\u0103d\u0103r\u0103u IA, P\u0103unescu H, Cioc\u00eerlan M. Association between liver cirrhosis and diabetes mellitus: A review on hepatic outcomes. J Clin Med. 2021. doi: https:\/\/doi.org\/10.3390\/jcm10020262","DOI":"10.3390\/jcm10020262"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World J Hepatol. 2020. doi: https:\/\/doi.org\/10.4254\/WJH.V12.I9.533","DOI":"10.4254\/wjh.v12.i9.533"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Maruyama H, Kobayashi K, Kiyono S, Yokosuka O. Interrelationship between insulin resistance and portal haemodynamic abnormality in cirrhosis. Int J Med Sci. 2017. doi: https:\/\/doi.org\/10.7150\/ijms.17738","DOI":"10.7150\/ijms.17738"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Nath P, Anand AC. Hepatogenous Diabetes: A Primer. J Clin Exp Hepatol. 2021. doi: https:\/\/doi.org\/10.1016\/j.jceh.2021.04.012","DOI":"10.1016\/j.jceh.2021.04.012"},{"key":"ref18","unstructured":"\u0415.\u0412. \u0411\u0438\u0440\u044e\u043a\u043e\u0432\u0430, \u0421.\u0412. \u0420\u043e\u0434\u0438\u043e\u043d\u043e\u0432\u0430. \u0421\u0430\u0445\u0430\u0440\u043d\u044b\u0439 \u0434\u0438\u0430\u0431\u0435\u0442 2-\u0433\u043e \u0442\u0438\u043f\u0430 \u0438 \u043d\u0435\u0430\u043b\u043a\u043e\u0433\u043e\u043b\u044c\u043d\u0430\u044f \u0436\u0438\u0440\u043e\u0432\u0430\u044f \u0431\u043e\u043b\u0435\u0437\u043d\u044c \u043f\u0435\u0447\u0435\u043d\u0438 \u2014 \u0431\u043e\u043b\u0435\u0437\u043d\u0438 \u0441\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u043e\u0441\u0442\u0438. \/\/ \u041c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0439 \u0410\u043b\u044c\u043c\u0430\u043d\u0430\u0445. \u2014 2017. \u2014 \u0422. 6. \u2014 \u0421. 130\u2013135."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Belfort R, Harrison SA, Brown K, et al. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. N Engl J Med. 2006. doi: https:\/\/doi.org\/10.1056\/nejmoa060326","DOI":"10.1056\/NEJMoa060326"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Aithal GP, Thomas JA, Kaye P V., et al. Randomized, PlaceboControlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis. Gastroenterology. 2008. doi: https:\/\/doi.org\/10.1053\/j.gastro.2008.06.047","DOI":"10.1053\/j.gastro.2008.06.047"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"LI Y, LIU L, WANG B, WANG J, CHEN D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Reports. 2013;1(1):57-64. doi: https:\/\/doi.org\/10.3892\/br.2012.18","DOI":"10.3892\/br.2012.18"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Zhang Z, Qi Y, Kong W, et al. Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease. Med Sci Monit. 2018;24:7399-7404. doi: https:\/\/doi.org\/10.12659\/MSM.911062","DOI":"10.12659\/MSM.911062"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Hayashizaki-Someya Y, Kurosaki E, Takasu T, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol. 2015;754:19-24. doi: https:\/\/doi.org\/10.1016\/j.ejphar.2015.02.009","DOI":"10.1016\/j.ejphar.2015.02.009"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Afsar B, Afsar RE. Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved. Clin Nutr. 2023;42(12):2338-2352. doi: https:\/\/doi.org\/10.1016\/j.clnu.2023.10.004","DOI":"10.1016\/j.clnu.2023.10.004"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ishikawa T, Shiratsuki S, Matsuda T, et al. Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension. J Gastroenterol. 2014;49(9):1333-1341. doi: https:\/\/doi.org\/10.1007\/s00535-013-0893-z","DOI":"10.1007\/s00535-013-0893-z"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Liu J, Ma J, Yang C, et al. Sarcopenia in Patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement. Radiology. 2022;303(3):711-719. doi: https:\/\/doi.org\/10.1148\/radiol.211172","DOI":"10.1148\/radiol.211172"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13443\/10844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T10:51:12Z","timestamp":1747997472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5,20]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13443","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}